SciClone Zadaxin fails Phase III hep C trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SciClone's immunomodulatory agent Zadaxin (thymalfasin) fails to demonstrate a statistically significant benefit in combination with pegylated interferon alpha for treatment of refractory hepatitis C, the firm announces Dec. 14. The 48-week trial is the first of two U.S. Phase III studies looking at Zadaxin in combination with peg-interferon alpha; sustained viral response (SVR) was the primary endpoint. "Although not statistically significant, 4% (10/269) of patients treated with Zadaxin plus pegylated interferon alpha achieved an SVR compared with only 2% (5/265) of patients treated with pegylated interferon alone," SciClone says. An ongoing Phase III triple therapy trial looking at the peg-interferon regimen plus ribavirin is being conducted by SciClone's European partner Sigma-Tau...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.